Our latest articles
Yet another US clinical hold hits, and this time the unlucky recipient is TG Therapeutics.
Biopharma takeouts in the $1-5bn range jumped in 2021, as rising valuations made their mark.
Small and mid-sized developers upped deal-making activity last year, a deep dive into M&A data finds.
Biomarkers and precise targeting could help the anti-TGF-β1 antibody SRK-181 succeed where bintrafusp failed, the group hopes.
But, judging by similar transactions, the valuation might not stay that high for long.
February will also see an outcome for Gilead's long-acting HIV therapy, and a key FDA panel for me-too checkpoint MAbs.
Tuck-ins are the order of the day, although new chief doesn’t rule out a large buy.
Momelotinib, a Jak inhibitor that has been through four companies, yields a positive result in its pivotal Momentum trial.
But further data do not shed much light on Onpattro’s chances in Apollo-B.
The agency takes its time – particularly with diagnostics.